The upside does not require a reactor moonshot. BWXT can grow by shedding lower-priority medical exposure, expanding commercial nuclear content through
PCG and related capacity, and using its trusted position to win more national-security and lifecycle work. A
premium multiple can persist because the company owns scarce qualified throughput, but it is still bounded by appropriations, licensing and long-cycle execution.